Filter

Subjects

Content Types

Countries

AID systems

API

Certificates

Data access

Data access restrictions

Database access

Database access restrictions

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
Found 61 result(s)
The COVID-19 Data Portal was launched in April 2020 to bring together relevant datasets for sharing and analysis in an effort to accelerate coronavirus research. It enables researchers to upload, access and analyse COVID-19 related reference data and specialist datasets as part of the wider European COVID-19 Data Platform.
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins experts in global public health, infectious disease, and emergency preparedness have been at the forefront of the international response to COVID-19. This website is a resource to help advance the understanding of the virus, inform the public, and brief policymakers in order to guide a response, improve care, and save lives. All data collected and displayed are made freely available through a GitHub repository https://github.com/CSSEGISandData/COVID-19, along with the feature layers of the dashboard, which are now included in the ESRI Living Atlas: https://livingatlas.arcgis.com/en/
The N3C Data Enclave is a secure portal containing a very large and extensive set of harmonized COVID-19 clinical electronic health record (EHR) data. The data can be accessed through a secure cloud Enclave hosted by NCATS and cannot be downloaded due to regulatory control. Broad access is available to investigators at institutions that sign a Data Use Agreements and via Data Use Requests by investigators. The N3C is a unique open, reproducible, transparent, collaborative team science initiative to leverage sensitive clinical data to expedite COVID-19 discoveries and improve health outcomes.
Country
Contains data on patients who have been tested for COVID-19 (whether positive or negative) in participating health institutions in Brazil. This initiative makes available three kinds of pseudonymized data: demographics (gender, year of birth, and region of residency), clinical and laboratory exams. Additional hospitalization information - such as data on transfers and outcomes - is provided when available. Clinical, lab, and hospitalization information is not limited to COVID-19 data, but covers all health events for these individuals, starting November 1st 2019, to allow for comorbidity studies. Data are deposited periodically, so that health information for a given individual is continuously updated to time of new version upload.
Research Collaborators & Institutions related to Coronavirus Epidemic Aim: Identify potential research experts or collaborators in areas related to the coronavirus epidemic across basic science, translational research, or clinical practice. Scope: A selection of Researchers active or cited in the area of Coronavirus, Middle East Respiratory Syndrome (MERS), SARS, etc.
To help flattening the COVID-19 curve public health systems need better information on whether preventive measures are working and how the virus may spread. Facebook Data for Good offer maps on population movement that researchers and nonprofits are already using to understand the coronavirus crisis, using aggregated data to protect people’s privacy.
The Infectious Diseases Data Observatory (IDDO) assembles clinical, laboratory and epidemiological data on a collaborative platform to be shared with the research and humanitarian communities. The data are analysed to generate reliable evidence and innovative resources that enable research-driven responses to the major challenges of emerging and neglected infections. Access is available to individual patient data held for malaria and Ebola virus disease. Resources for visceral leishmaniasis, schistosomiasis and soil transmitted helminths, Chagas disease and COVID-19 are under development. IDDO contains the following repositories : COVID-19 Data Platform, Chagas Data Platform, Schistosomiasis & Soil Transmitted Helminths Data Platform, Visceral Leishmaniasis Data Platform, Ebola Data Platform, WorldWide Antimalarial Resistance Network (WWARN)
Novartis provides the technical results and trial summaries for patients from Phase 1 through 4 interventional trials for innovative products within one year of trial completion. A trial summary for patients is a trial result written in easier to understand language than the technical results.
Country
Risklayer Explorer is a collaboration between Risklayer GmbH and the Karlsruhe Institute of Technology's Center for Disaster Risk Management and Risk Reduction Technology (CEDIM). This website is still under development, but we are going live with it already, because we want to present data on the Novel Coronavirus (COVID-19) to help inform the public of the current situation. You will be able to track disaster events and read about our analysis here. Our work is a continuation of a new style of disaster research started by CEDIM in 2011 to analyze disasters immediately after their occurrence, assess the impacts, and retrace the temporal development of disaster events. We are already analyzing damaging earthquakes globally, providing you with event characteristics, earthquake's intensity footprints, as well as the population affected by earthquakes. In addition to earthquake events, we expect to be tracking and analyzing tropical cyclone, volcano and extreme weather events in 2020.
The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.
Country
The UMIN case data repository system was implemented by adding a function to the UMIN Clinical Trials Registry System. The aim of this system is to keep anonymized case data from clinical research conducted by individual researchers at the UMIN center, and to guarantee the content of the data to third parties. This system enables other researchers to inspect case data or to repeat statistical analyses
Country
The mission of ChiCTR is to “unite clinicians, clinical epidemiologists, biostatisticians, epidemiologists and healthcare managers both at home and abroad, to manage clinical trials in a strict and scientific manner, and to promote their quality in China, so as to provide reliable evidence from clinical trials for health care workers, consumers and medical policy decision makers, and also to use medical resources more effectively to provide better service for Chinese people and all human beings.
MassIVE is a community resource developed by the NIH-funded Center for Computational Mass Spectrometry to promote the global, free exchange of mass spectrometry data. MassIVE datasets can be assigned ProteomeXchange accessions to satisfy publication requirements.
Country
DisGeNET is a discovery platform containing one of the largest publicly available collections of genes and variants associated to human diseases. DisGeNET integrates data from expert curated repositories, GWAS catalogues, animal models and the scientific literature. DisGeNET data are homogeneously annotated with controlled vocabularies and community-driven ontologies. Additionally, several original metrics are provided to assist the prioritization of genotype–phenotype relationships.
INDI was formed as a next generation FCP effort. INDI aims to provide a model for the broader imaging community while simultaneously creating a public dataset capable of dwarfing those that most groups could obtain individually.
Content type(s)
The NTR is a publicly accessible and freely searchable prospective trial register in which studies are registered that run in the Netherlands or are carried out by Dutch researchers. Primary Registries have been recognized and accepted by the WHO and ICMJE. If your study is included in one of these registers, you meet the registration requirements. For the Netherlands the NTR is the Primary Registry.
Country
ProteomicsDB (https://www.ProteomicsDB.org) started as a protein-centric in-memory database for the exploration of large collections of quantitative mass spectrometry-based proteomics data. The data types and contents grew over time to include RNA-Seq expression data, drug-target interactions and cell line viability data.
WorldData.AI comes with a built-in workspace – the next-generation hyper-computing platform powered by a library of 3.3 billion curated external trends. WorldData.AI allows you to save your models in its “My Models Trained” section. You can make your models public and share them on social media with interesting images, model features, summary statistics, and feature comparisons. Empower others to leverage your models. For example, if you have discovered a previously unknown impact of interest rates on new-housing demand, you may want to share it through “My Models Trained.” Upload your data and combine it with external trends to build, train, and deploy predictive models with one click! WorldData.AI inspects your raw data, applies feature processors, chooses the best set of algorithms, trains and tunes multiple models, and then ranks model performance.
Content type(s)
The global scientific community, international partners, the private sector, civil society, and other relevant stakeholders establish a voluntary platform to link clinical trials registers in order to ensure a single point of access and the unambiguous identification of trials with a view to enhancing access to information by patients, families, patient groups and others.
The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable. ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base. ISRCTN accepts all studies involving human subjects or populations with outcome measures assessing effects on human health and well-being, including studies in healthcare, social care, education, workplace safety and economic development.
ArcGIS 'Living Atlas of the World is a unique collection of worldwide geographic information. It contains maps, apps and data layers that support you in your work. Corona Virus resources https://coronavirus-resources.esri.com/
The Complex Portal is a manually curated, encyclopaedic resource of macromolecular complexes from a number of key model organisms, entered into the IntAct molecular interaction database (https://www.ebi.ac.uk/intact/). Data includes protein-only complexes as well as protein-small molecule and protein-nucleic acid complexes. All complexes are derived from physical molecular interaction evidences extracted from the literature and cross-referenced in the entry, or by curator inference from information on homologs in closely related species or by inference from scientific background. All complexes are tagged with Evidence and Conclusion Ontology codes to indicate the type of evidence available for each entry.
ViralZone is a SIB Swiss Institute of Bioinformatics web-resource for all viral genus and families, providing general molecular and epidemiological information, along with virion and genome figures. Each virus or family page gives an easy access to UniProtKB/Swiss-Prot viral protein entries.